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Abstract
Animal models of hemophilia and related diseases are important for development of novel
treatments and to understand the pathophysiology of bleeding disorders in humans. Testing in
animals with the equivalent human disorder provides informed estimates of doses and measures of
efficacy, which aids in design of human trials. Many models of hemophilia A, hemophilia B, and
von Willebrand disease have been developed from animals with spontaneous mutations
(hemophilia A dogs, rats, sheep; hemophilia B dogs; and von Willebrand disease pigs and dogs),
or by targeted gene disruption in mice to create hemophilia A, B, or VWD models. Animal models
have been used to generate new insights into the pathophysiology of each bleeding disorder and
also to perform pre-clinical assessments of standard protein replacement therapies as well as novel
gene transfer technology. Both the differences between species and differences in underlying
causative mutations must be considered in choosing the best animal for a specific scientific study
Importance of Animal Models for Study of Human Bleeding Disorders
Animal models are important for FDA-required pre-clinical assessment of safety prior to
testing of novel therapeutics in humans. If testing can be done in animals with the equivalent
of the human disease under study, better informed estimates of dose finding can be obtained
(pharmacokinetics), and measures of efficacy can be tested (pharmacodynamics), which aid
in pre-clinical assessment of the drug and design of human trials. Apart from drug
development, animal models of human disease are also important for understanding the
pathophysiology of those diseases.
There are many potential disadvantages and limitations to animal models of human diseases,
including immune reactions to human proteins, different metabolism or clearance of human
proteins by different species, and different tissue tropism of viral vectors in animals
compared to humans. Despite these limitations, animal models of hemophilia and related
bleeding disorders provide insights into the pathophysiology of human disease.
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Several animal models identified after spontaneous occurrences or engineered by targeted
gene disruption recapitulate human hemophilia and other bleeding diseases. Models arising
from spontaneous mutations usually have clear hemorrhagic phenotypes, since they are only
identified by overtly abnormal bleeding. “Knock-out” animals (usually mice) often do not
have spontaneous bleeding despite equally low levels of coagulant proteins. For hemophilia
and related bleeding disorders, animal models (spontaneous or engineered) have not only
informed our understanding of the natural history and pathophysiology of the disease but
also guided development of therapeutics in humans. Each model can provide
complementary information on the pathophysiology of bleeding disorders and novel
therapeutics for their treatment--especially important for development of gene therapy, in
which unique toxicities such as insertional mutagenesis, germ line gene transfer, and viral
toxicities, must be studied.
Hemophilia A Animals
Hemophilia A Dogs
The first hemophilia animal model arose when a dog breeder noticing prolonged bleeding
after clipping of the nails of a particular Irish setter dog (Figure 1). This was brought to the
attention of pathologist Kenneth M. Brinkhous at the University of North Carolina at Chapel
Hill who showed complete deficiency of coagulation factor VIII.1, 2 From that animal he
established a colony of hemophilia A dogs that has been studied since 1947. The bleeding
phenotype replicates that of severe hemophilia A in humans, with spontaneous soft tissue
hemorrhage, hemarthroses, and occasional mucosal bleeding. Thrombin generation in vitro
is defective. From the observation of prolonged bleeding with nail clipping came a
standardized cuticle bleeding time method that predicts hemostasis.3 Bleeding can be treated
or prevented by administration of canine plasma, canine cryoprecipitate, or recombinant
canine factor VIII,4 as is true for humans with hemophilia A. The basis of the factor VIII
deficiency is a gene inversion in which recombination occurs between an actively
transcribed gene that is inside intron 22 of the factor VIII gene on the X chromosome and a
copy ~0.5 Mb upstream of the factor VIII gene.5 This results in the first 22 exons of the
factor VIII gene being transcribed normally, but exons 23-26 are replaced with a non-factor
VIII sequence.
At Queens University in Toronto, Canada, a separate hemophilia A dog colony was
established in 1980 from an affected miniature schnauzer (Figure 2).6 The bleeding
phenotype was severe, as in the Chapel Hill colony. As in the Chapel Hill colony, there is no
circulating factor VIII, and interestingly, the Canadian colony has the same aberrant factor
VIII transcript is seen in the Chapel Hill dogs.7 An identical factor VIII transcript arising in
different breeds, different places and different decades suggests a common mutation
mechanism. This involves repeated DNA elements like those that undergo spontaneous
homologous recombination in humans.8-10 Dogs from the Queens University hemophilia A
colony notably have a greater rate of forming inhibitor antibodies (“inhibitors”) to dog factor
VIII when transfused to treat or prevent bleeding.11 Notably, the hemophilia A dogs in
Canada have two amino acid polymorphisms at position 909 (Gly/Ser) and 1184 (Leu/Pro)
that differ from factor VIII from normal dogs used for replacement therapy.12 This finding
raises the possibility that factor VIII peptides differing at these sites may be recognized as
foreign, and thereby provoke antibody formation. A similar explanation has been proposed
for the increased risk of inhibitor development in humans of African ancestry with
hemophilia A, who have a greater prevalence of rare factor VIII polymorphisms.13 The
Chapel Hill and Queens University hemophilia A dog colonies, with a common gene
inversion mutation could be used to study the contribution to inhibitor risk of minor
mismatches in protein coding sequence.
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Other spontaneous mutations in the factor VIII gene have been observed in hemophilia A
dogs.14 For the most part, these are pets that are not used in biomedical research. However
their existence makes it clear that various mutations in the factor VIII gene do occur
spontaneously. One mutation causes a premature stop codon in exon 12 that is analogous to
a human mutation associated with a severe hemophilia (unpublished data, J Lozier and TC
Nichols).
The hemophilia A dogs in Chapel Hill and Queens University have been used for pre-
clinical trials of human factor VIII concentrates,15-18 novel hemophilia A therapeutics,19-21
and recombinant activated factor VII, a direct activator of factor X that circumvents factor
VIII inhibitors.22-24 More recently, gene therapy for hemophilia A is progressing to clinical
applications in man, and hemophilia A dogs have been used to test various adenovirus and
adeno-associated virus (AAV) vectors both for safety and efficacy.25-33
Hemophilia A Sheep
In 1979, Swiss researchers documented occurrence of severe hemophilia A in male offspring
of an alpine white ewe, manifesting initially as umbilical cord bleeding after birth.
Laboratory testing indicated < 1% factor VIII activity, consistent with severe hemophilia
A.34,35 It was also demonstrated that the factor VIII gene in sheep maps to the X
chromosome, like humans and dogs.36 Further breeding of the same ewe gave rise to
additional affected progeny, and though the line was not continuously maintained, semen
from affected males was cryopreserved. In 2009, Porada et al reported re-establishment of
the hemophilia A sheep by multiple ovulation embryo transfer, and in vitro fertilization
using intracytoplasmic sperm injection.37 They also were able to amplify the factor VIII
mRNA from the spleen of an affected animal, and identified a premature stop codon in exon
14 of the factor VIII gene.37 Soft tissue hemorrhage, hemarthroses, and hematuria occurred
spontaneously, and were responsive to treatment with human factor VIII (Figure 3). Like
dogs with hemophilia A, there was prolonged bleeding with cuticle clipping. The
hemarthropathy of the hemophilia A sheep is more pronounced than in the hemophilia A
dogs, but replacement therapy is more aggressive in the dogs. Although the sheep can be
kept from bleeding to death with human factor VIII, they are prone to make anti-human
factor VIII antibodies, due to the differences between each species’ factor VIII. If sheep
factor VIII were more readily available for prophylaxis and treatment of bleeding, this
species would be a more practical model.
Recently, correction of the bleeding phenotype in hemophilia A sheep by implantation of
genetically modified mesenchymal stromal cells (MSCs) obtained from bone marrow was
reported. Two sheep with hemophilia A treated with human factor VIII developed antibodies
to the human protein, and became refractory to treatment. MSCs derived from a parent of
the sheep were transduced with a lentivirus vector containing the porcine factor VIII gene,
and transduced MSCs were repeatedly implanted into the peritoneum of each hemophilia A
sheep. The bleeding, especially the hemarthroses, diminished dramatically in each animal.38
Eventually inhibitor titers rose dramatically in each animal, due to antibodies that cross-
reacted with porcine and human factor VIII. On necropsy, lentiviral transduced MSCs were
distributed widely, including the synovium of affected joints. Thus, local delivery of factor
VIII to tissues in amounts that are not detectable in the systemic circulation may ameliorate
bleeding.
Hemophilia A Mice
Mice are less expensive to house and maintain in large numbers, so researchers sought
examples of mice with hemophilia A but were unsuccessful, even though hemophilia A dogs
and sheep were readily identified. In theory, complete deficiency of factor VIII could be an
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embryonic lethal event. Conversely, the bleeding phenotype of factor VIII deficiency in
animals such as mice may be mild and therefore undetectable. Eventually, through
embryonic stem cell manipulation, two factor VIII deficient knockout mouse strains were
engineered by Bi et al in 1995.39 In one strain exon 16 of the mouse factor VIII gene was
interrupted by cre-lox mediated recombination strategies, and in another, exon 17 was
disrupted. The mice had no detectable circulating factor VIII, but somewhat surprisingly,
little or no apparent spontaneous bleeding, in contrast to hemophilia A dogs and sheep.40
Incised wounds and tail clipping reliably resulted in fatal bleeding, but blood collection from
the retro-orbital venous plexus with glass capillaries was surprisingly uneventful
(unpublished observations, JNL). This has practical importance for investigators, since
collection of blood by retro-orbital puncture is quick and requires no precautions to prevent
exsanguination, whereas tail transection to collect blood requires cauterization to prevent
exsanguination. In hemophilic mice, methods to assess hemostasis by transection of the tail
at a site of defined size/caliber, and quantifying blood loss can assess the amount of factor
VIII in circulation.41 The factor VIII knockout mice have no circulating factor VIII protein
and therefore are a fairly “clean” system in which to measure factor VIII after administration
of the protein or factor VIII gene transfer. Mice typically make antibodies to human factor
VIII, whether exposed to factor VIII protein or subjected to factor VIII gene transfer in vivo.
In normal mice the predilection towards making antibodies is strain-dependent, and likely
related to MHC genes. Hemophilia A mice can be bred into immunodeficient strains of mice
to create hemophilic mice that do not make antibodies to human factor VIII protein (e.g.,
NOD-SCID hemophilia A mice).42 In such animals, experiments in factor VIII gene transfer
can be undertaken with no risk of developing neutralizing antibodies to human factor VIII,
for instance.
Although the mouse has the equivalent of the F8A gene seen in humans and dogs, there is
only one copy of that gene, residing outside the nearby mouse factor VIII gene on the X
chromosome.43 This molecular biology explains why there can be no homologous
recombination to mediate a factor VIII gene inversion. Although in mice spontaneous factor
VIII gene mutations could occur by other mechanisms, the factor VIII knockout mice
suggest spontaneous bleeding probably would not occur. The body mass of a mouse is
negligible compared to that of larger mammals, and the weight is carried much closer to the
ground. Finally, mice carry body weight on four joints (rather than two). The spontaneous
hemarthroses routinely seen in humans, dogs, and sheep are most common in the weight-
bearing surfaces of the knee, ankle, or hip that bear much more weight than for the mouse.
The hemophilia A knockout mice remain a critical “entry level” animal model for testing of
therapeutics of all kinds (protein replacement, gene therapy, etc.) since small amounts of
precious research reagents can serve to test many small animals prior to scale up in larger
animals. One key limitation of mice is that functional assays of factor VIII coagulant activity
require large volumes of blood, a significant practical problem.
Hemophilia A Rats
A group at Yale identified inbred animals from the WAG/RijY rat strain in which there is
bruising, soft-tissue hemorrhage, and hemarthroses of the tarsal joints typical of human
hemophilia A (Figure 4).44 The affected animals, designated WAG/RijYcb, came to
attention after a subcutaneous injection in a male rat caused a hematoma. Some male and
female littermates of the index case were likewise prone to bleed and all had prolonged
activated partial thromboplastin times. A missense mutation of the factor VIII gene was
found in which proline is substituted for leucine at amino acid 176 of the factor VIII
protein.45 In contrast to humans, dogs, sheep, and mice, the factor VIII gene in rats is
located on chromosome 18, rather than the X chromosome, which explains the autosomal
Lozier and Nichols Page 4













recessive pattern of inheritance. The presence of an autosomal hemophilia animal model




Severe bleeding with trauma or surgery, and arthritic signs/symptoms of recurrent
hemarthroses were noted in Cairn terriers in Toronto, Canada that were shown to be
deficient in coagulation factor IX (Figure 5).46 The inheritance pattern was sex-linked, like
human hemophilia B. Complementation studies with serum from humans deficient in factor
VIII, IX, XI, or XII confirmed factor IX deficiency. The gene defect was found to be a point
mutation in factor IX that results in substitution of glutamic acid for glycine at amino acid
379 in the catalytic domain.47 The mutation is remarkable in that there is no detectable
circulating factor IX protein in the plasma, and apparently the protein is so unstable that it is
not secreted into the circulation.
A different hemophilia B dog colony was established at Auburn in Alabama after severe
bleeding was observed in Lhasa Apso dogs that were deficient in factor IX. The factor IX
gene sequence showed a 5 bp deletion at nucleotides 772-776 and a C to T transition at
nucleotide 777 resulting in a frame-shift and a premature stop codon at amino acid 146 in
the factor IX protein.48 The mutation eliminates the catalytic domain of the factor IX
protein, and there is almost no detectable mRNA or translated protein. In contrast to the
Chapel Hill hemophilia B dogs, the Auburn dogs are prone to develop factor IX inhibitors
when exposed to canine factor IX.49 It is not clear if this is due to the different underlying
mutations, or whether the particular dogs into which these mutations have been bred have
different histocompatibility locus genes, for instance. Inhibitor antibodies to canine factor IX
have also been demonstrated in a Labrador retriever dog with hemophilia B in which there is
a complete deletion of the canine factor IX gene.50
Hemophilia B Mice
There have been no mice identified with hemophilia B from spontaneous factor IX
mutations, perhaps for the same reason that no mice were identified with hemophilia A from
spontaneous factor VIII mutations. Therefore a series of factor IX deficient mice were
engineered by targeted disruption of the mouse factor IX gene.51-53 These mice have a
bleeding phenotype like that of the hemophilia A knockout mice: little spontaneous bleeding
and prolonged (even fatal) bleeding after tail clipping or most other invasive procedures.
Also, like the hemophilia A mice, blood collection by retro-orbital puncture does not cause
serious bleeding (JNL, unpublished observations).
After generation of factor IX knock-out mice, it became possible to engineer “knock-in”
mice that express human factor IX.54 This permitted in vivo testing of structure/function
relationships using human factor IX constructs. A knock-in mouse has been described in
which glutamine replaces arginine at amino acid 333 in the catalytic domain of human factor
IX (R333Q-hFIX), a point mutation seen in some humans with hemophilia B.54 Another
knock-in mouse has been created in which lysine at amino acid 5 is mutated to alanine,
which impairs binding of the factor IX protein to type IV collagen.55 Interestingly, in vitro
factor IX activity of this variant is normal, but in vivo hemostasis is impaired, though not as
much as in the factor IX knockout mouse.55 These animals are useful in studies on the effect
of factor IX mutations in residual circulating protein on immunogenicity of factor IX. For
instance, human factor IX expression in knockout mice by adeno-associated virus vectors
typically results in antibody formation, whereas in the R333Q-hFIX knock-in, there is no
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inhibitor antibody formation after human factor IX gene expression.56 Factor IX protein
(even if non-functional), is protective against antibody formation. Most humans with
hemophilia B have (defective) circulating factor IX protein and are not prone to make
inhibitors when treated with factor IX concentrates.
Immunologic insights can also be derived from normal (non-hemophilic) miceA survey of
various mouse strains indicated that A/J mice were high responders to human factor IX and
C57BL/6J mice were non-responders.57 By measuring antibodies to human factor IX in
recombinant inbred and congenic mice derived from A/J and C57BL/6J strains it was
possible to show that the MHC complex on chromosome 17, IL10 and interferon-γ genes
were linked to the immune response to human factor IX.57
Gene therapy in humans has advanced more rapidly for hemophilia B than for hemophilia A
or VWD since the shorter factor IX coding sequence makes gene transfer vector
construction easier, and factor IX gets into the circulation readily after expression in most
tissues types. Hemophilia B dogs and mice have been essential for pre-clinical testing of
factor IX gene transfer vectors that are being developed. Hemophilia B models have
predicted the dose of vector required to achieve clinically significant factor IX levels, the
immunogenicity of expressed factor IX, toxicity of vectors, and the effect of novel factor IX
variants on gene expression in vivo. 58-65 Information derived in mice and dogs is usually
comparable, but each animal provides complementary information, as described for
hemophilia A models. The most important recent work in hemophilia B animal models has
been in support of clinical trials of AAV-factor IX gene transfer into skeletal muscle66 or
liver67, 68 for hemophilia B in humans.
Von Willebrand Disease Animals
VWF is a large plasma protein that exists as a globular protein under low shear conditions,
but under high shear conditions it unfolds into a linear protein.69 It binds subendothelial
collagen and platelets through the various platelet receptors and plasma proteins (e.g., GpIb/
IX/V, GpVI, GpIV, thrombospondin, fibrinogen, etc.),70 thereby mediating platelet adhesion
to injured endothelium. Under high-shear conditions, binding to GpIb is most critical.71
VWF can form multimers with enhanced ability to bind platelets to each other or
subendothelial collagen. VWF is synthesized in megakaryocytes and in the endothelial cell,
and is stored in the alpha granule of the platelet and Weibel-Palade body of the endothelial
cell. Virtually all plasma VWF is derived from endothelial cells in humans, and platelet
VWF is secreted only with platelet activation. A second critical role of VWF is to stabilize
factor VIII. The absence of VWF leads to accelerated clearance of factor VIII and in mild
(type 1) VWD where the VWF level is ~30-50% of normal, the factor VIII may be low
enough to slightly prolong the activated partial thromboplastin time. However, in type 1
VWD, the bleeding manifestations are primarily those of impaired platelet function, namely
mucosal bleeding.72 In severe (type 3) von Willebrand disease, VWF levels are less than
10%, factor VIII levels are also typically less than 10%, and there can be soft tissue
hemorrhage and hemarthroses typical of hemophilia in addition to the mucosal bleeding
from VWF deficiency.72
Many insights into VWF biochemistry and physiology are derived from the animal models
of VWD in mice pigs, and dogs. Dogs do not have VWF in their platelets,73, 74 whereas pigs
have both megakaryocyte75 and endothelial cell-derived VWF76 like humans, which is a
critical issue for modeling human VWD. Inheritance of VWD is autosomal in humans, dogs,
pigs and mice, in contrast to sex-linked hemophilias A and B. Pigs and dogs share 84-86%
VWF amino acid sequence identity (with many additional highly conserved amino acids),
and have conservation of the major domains for binding of platelets, factor VIII, collagen,
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and heparin.77,78 In pigs and dogs with VWD, human VWF mediates platelet adhesion in
vitro and in vivo, likely through the conserved RGD integrin motif found in all three species
that interacts with the platelet αIIb/βIII surface receptor. Human factor VIII is stabilized by
porcine or canine VWF and human VWF stabilizes porcine or canine factor VIII. Thus,
these two species are well-suited for study of VWD.
von Willebrand Disease Dogs
Von Willebrand disease is fairly common in dogs, and a model of VWD was developed
from a Scottish Terrier show dog, first identified in 1978, and studied thereafter at the
University of North Carolina at Chapel Hill (Figure 6).79 The causative mutation is a single
nucleotide deletion in exon 4 of the VWF gene that causes premature termination of the
protein; there is no detectable VWF mRNA or protein.73 The dogs can be bred either to
produce severe (type 3) VWD animals with two defective alleles, or the milder (type 1)
VWD animals in which one copy of the gene is defective. The former are especially useful
for pre-clinical study of human VWF concentrates.80, 81 In the mild (type 1) VWD dogs,
desmopressin can be used to discharge VWF from Weibel-Palade bodies in the endothelial
cells. It has been shown in VWD dogs that IL-11 results in increased VWF message
transcription and increased plasma levels of VWF.82 Weibel-Palade body stores of VWF
releasable with desmopressin are also increased with IL-11. Unlike type 1 VWD where
desmopressin therapy results in tachyphylaxis after a few doses, the responsiveness to
desmopressin persists when given after/during administration of IL-11. As expected, in
severe VWD where both gene copies are defective, there is no effect of desmopressin or
IL-11.82 The studies in VWF dogs were the basis for successful phase II clinical trials in
humans reported by Ragni et al.83-85
Von Willebrand Disease Pigs
Pigs with VWD have been studied in detail over the years (Figure 7), and have provided
many insights into the pathophysiology of VWD in humans. Like dogs VWD in pigs is
transmitted as an autosomal trait. In contrast to the VWD dogs the VWF gene mutation in
the pig is not known. However, linkage to the VWF gene has been demonstrated, and there
are no gross rearrangements of the VWF gene, suggesting a point mutation or small deletion
may be responsible.86 The VWF message is present but at reduced levels, and low amounts
of VWF antigen can be detected in VWD pigs’ platelets and endothelial cells.76
Von Willebrand Disease Mice
The level of von Willebrand factor in mice varies widely (not unlike humans) and in 1990
the inbred mouse strain RIIIs/J was noted to have ~50% of the normal mouse VWF level
and a prolonged bleeding time after tail clipping; accordingly, it was proposed to be a model
of human type 1 VWD.87 By taking advantage of the marked variation of VWF levels
between various mouse strains, it was possible to identify the locus Mvwf (for “modifier of
VWF”) on chromosome 11 (distinct from the VWF gene on mouse chromosome 12)
associated with the low VWF levels88, 89 As it turns out, Mvwf is a polymorphism in
Galgt2, a glycosyltransferase gene.90 The mutated Galgt2 gene is expressed abnormally in
endothelial cells, and altered glycosylation of VWF in the RIIIS/J strain causes accelerated
turnover and decreased levels of VWF.
In addition to spontaneous VWD in certain mouse strains of due to modifier genes, a
knockout mouse with no detectable VWF in the circulation was generated by targeted VWF
gene disruption.91 Spontaneous bleeding is not typical for the knockout mouse, but there is
prolonged bleeding with tail clipping. Like dogs and pigs with VWD, mice with two
defective alleles have severe (type 3) VWD and mice with one defective allele have mild
(type 1) VWD. As typical of all VWD animal models, factor VIII levels are decreased to
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15-20% in the severe homozygous mice with type 3 VWD, and factor VIII levels of 50-60%
are seen in heterozygotes.91 Since VWD mice can be bred into other strains with well-
defined genetic make-up, and mice are less expensive to maintain than large animals, the
VWD mice are being used in more laboratories than the large animals with VWD.
Von Willebrand disease animal models have been used to show that the Weibel-Palade body
of the endothelial cell is comprised largely of condensed multimers of VWF; the Weibel-
Palade body is missing in type 3 VWD pigs, dogs, or knockout mouse endothelial cells and
expression of canine VWF in VWD dog endothelial cells restored them.73, 92, 93
Summary
Animal models of hemophilia and related bleeding disorders have provided us with
fascinating insights into pathophysiology of bleeding, common mechanisms for gene
mutation, normal and abnormal biochemistry/metabolism of coagulation factors, and
strategies for treatment of human disease. Their use will continue to be critical for ongoing
development of novel therapies, especially gene therapy.
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Irish Setter hemophilia A index case, University of North Carolina at Chapel Hill (photo by
William Brinkhous).
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Queen's University Hemophilia A dogs, early in existence of the colony. Pictures courtesy
of Dr. David Lillicrap, Queen's University, Kingston, Ontario, CA.
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Sheep with hemophilia A, depicting swollen and hemorrhagic knees from acute and chronic
hemarthoses. Figure modified from Porada, CD, et al.37
Lozier and Nichols Page 15














Hemophilia A Rat WAG/RijYcb strain, with tarsal joint bleed. From Booth CJ, Brooks MB,
Rockwell S.44
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Hemophilia B dog, a Keagle (mix of Cairn terrier and beagle) from University of North
Carolina at Chapel Hill.
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Scottish terrier dog with von Willebrand disease, from University of North Carolina at
Chapel Hill.
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von Willbrand disease pig from University of North Carolina at Chapel Hill.
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